GlassScriptPhysician profile
Madhu Sharma
NPI 1669430161
$2,168.38
in general payments reported to CMS, 2019-2025
15 companies · $68.10 in 2025
The $68.10 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $228 · 2021: $658 · 2022: $285 · 2023: $305 · 2024: $181 · 2025: $68.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.02 | 2019-2024 | Linzess, Viberzi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $328.70 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.39 | 2019-2024 | Xifaxan |
| Ardelyx, INC. | $129.86 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $114.38 | 2019-2021 | |
| Qol Medical, LLC | $112.79 | 2020-2023 | Sucraid |
| Redhill Biopharma INC. | $90.88 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Intercept Pharmaceuticals, INC. | $38.29 | 2019 | |
| Ferring Pharmaceuticals INC. | $35.01 | 2019-2023 | Rebyota |
| Celgene Corporation | $32.99 | 2021 | |
| Janssen Biotech, INC. | $30.18 | 2024 | Simponi, Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $29.09 | 2025 | Iqirvo |
| Phadia US INC. | $23.65 | 2022 | |
| Albireo Pharma, INC. | $21.06 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $19.09 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhu Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.